Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Victory Capital Management Inc.

Victory Capital Management Inc. increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 10.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,909 shares of the biopharmaceutical company's stock after buying an additional 4,229 shares during the quarter. Victory Capital Management Inc.'s holdings in Alnylam Pharmaceuticals were worth $11,801,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of ALNY. Hollencrest Capital Management bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $29,000. Ashton Thomas Private Wealth LLC purchased a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at about $26,000. Washington Trust Advisors Inc. bought a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $42,000. Allspring Global Investments Holdings LLC boosted its holdings in Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 143 shares in the last quarter. Finally, Friedenthal Financial purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth about $51,000. Hedge funds and other institutional investors own 92.97% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Wells Fargo & Company boosted their price objective on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an "equal weight" rating in a report on Friday, August 2nd. Chardan Capital restated a "buy" rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their price objective for the company from $198.00 to $370.00 in a research report on Friday, August 16th. TD Cowen boosted their price objective on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a "buy" rating in a research report on Monday, October 21st. Finally, Barclays boosted their price objective on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an "overweight" rating in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $298.09.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $248.79 on Thursday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a market cap of $32.09 billion, a PE ratio of -94.96 and a beta of 0.39. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The company's fifty day simple moving average is $273.83 and its 200-day simple moving average is $236.76.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. The company's quarterly revenue was down 33.3% on a year-over-year basis. During the same period last year, the firm posted $1.15 earnings per share. As a group, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.22 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.